Heart failure in women: An equal opportunity player in the expanding epidemic of heart failure
| Autor: | Jill Kalman, Gerin R. Stevens |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Pharmacology
medicine.medical_specialty education.field_of_study business.industry Incidence (epidemiology) Population Disease medicine.disease Clinical trial Valsartan Internal medicine Heart failure Cardiology Etiology Medicine Pharmacology (medical) business Intensive care medicine education Carvedilol medicine.drug |
| Zdroj: | Current Cardiovascular Risk Reports. 2:210-216 |
| ISSN: | 1932-9563 1932-9520 |
| DOI: | 10.1007/s12170-008-0040-1 |
| Popis: | Heart failure has been described as an epidemic with increasing incidence and prevalence with the aging of the general population. Sex plays an important role in heart failure management given that women with heart failure typically are older, have nonischemic etiologies more often, and have better ventricular function than men with heart failure. This translates into better outcomes for women regardless of the cause of heart failure. Important differences exist in disease in women and men admitted with heart failure, and diagnostic and treatment strategies significantly differ. Despite a National Institutes of Health mandate in 1993, women are still underrepresented in clinical trials, making it difficult to extrapolate treatment data in a meaningful way. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink